

HealthCare Global Enterprises Ltd. reports Q2 FY17 results

Revenue growth of 21% (y-o-y)

EBITDA growth of 26% (y-o-y)

PAT of INR 49 mn

Bengaluru, November 10, 2016: Healthcare Global Enterprises Limited (“HCG”) today announced its financial results for the quarter ended September 30, 2016 (“Q2 FY17”).

Highlights for the quarter ended September 30, 2016 (Q2 FY17)

- Consolidated Income from Operations (“Revenue”) was **INR 1,740 mn** as compared to **INR 1,439 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **21%**.
- Consolidated Profit Before Other Income, Depreciation and Amortisation, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was **INR 254 mn** as compared to **INR 202 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **26%**.
- Profit before Taxes and Exceptional items (“PBT”) was **INR 76 million** as compared to a **profit of INR 16 mn** in the corresponding quarter of the previous year.
- Profit after Taxes and Minority Interest (“PAT”) was **INR 49 million** as compared to a **loss of INR 17 mn** in the corresponding quarter of the previous year.
- EBITDA excluding losses from new centres was **INR 272 mn**, reflecting a margin of **17.2%** and a growth of **27 %** over the corresponding quarter of the previous year.

INR million except per share data

Period Ended Sept 30	Q2-FY17	Q2-FY16	Growth (y-o-y)	H1-FY17	H1-FY16	Growth (y-o-y)
Income from Operations	1,739.8	1,439.4	20.9%	3,415.3	2,856.8	19.5%
EBITDA⁽¹⁾	254.0	202.0	25.7%	490.3	390.4	25.6%
<i>EBITDA Margin (%)</i>	<i>14.6%</i>	<i>14.0%</i>		<i>14.4%</i>	<i>13.7%</i>	
PBT⁽²⁾	76.1	16.4	NM	154.9	19.2	NM
<i>PBT Margin (%)</i>	<i>4.4%</i>	<i>1.1%</i>		<i>4.5%</i>	<i>0.7%</i>	
PAT⁽³⁾	49.4	(16.7)	NM	99.2	(21.7)	NM
<i>PAT Margin (%)</i>	<i>2.8%</i>	<i>-1.2%</i>		<i>2.9%</i>	<i>-0.8%</i>	
Earnings Per Share	0.58	(0.23)	NM	1.16	(0.30)	NM

(1) Profit before other income, depreciation and amortization, finance costs, exceptional items and taxes

(2) Profit / (Loss) before tax and exceptional items

(3) Profit / (Loss) for the period

Business Updates for Q2 FY17

- New cancer centres at Kalaburagi, Vadodara and Visakhapatnam, and our multispeciality hospital at Bhavnagar continues to ramp.
- Our cancer centre at Vijayawada has been successfully revamped and has shown strong operational performance.
- Strong adoption of the daVinci robotic surgery system at our Bengaluru and Ahmedabad centres, with over 100 procedures completed.
- Precision oncology advancements include the launch of our NGS facility as well as the development of new liquid biopsy tests that have the potential to transform the standard of care in cancer.
- Clinical innovations include the development of 3-D printing in the treatment of tongue cancers, and a novel surgical oncology technique for excision of carotid artery tumors.

Commenting on the results, **Dr. B.S. Ajaikumar, Chairman, HealthCare Global Enterprises Ltd.** said, “We are pleased to report continued strong results for the second quarter of FY 2017. HCG is at the forefront in the battle against cancer. We are making significant advances in the field of precision oncology and are seeing robust adoption of new technologies across our network that will drive superior clinical outcomes. We also continue to expand our footprint and market share across India thanks to our model of comprehensive cancer care and partnership with specialist doctors. We are also seeing strong progress in building our Milann network in addition to the current 6 centres. Overall we see good growth prospects in our business across the board. With 8 new comprehensive cancer centres under development we continue to progress towards our mission to make high quality cancer care accessible to all.”

Q2 FY17 Earnings Call

The company will conduct a one hour conference call at **5:30 PM IST on Thursday, November 10, 2016** where the management will discuss insights about the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is **+91 22 3960 0663 / +91 22 6746 8363** . Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.

About HCG Enterprises Ltd.:

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 17 comprehensive cancer centres across India, HCG has brought advanced cancer care to the doorstep of millions of people. HCG’s comprehensive cancer centres provide expertise and advanced technologies required for the effective diagnosis and treatment of cancer under one roof. HCG has pioneered the introduction and adoption of several technologies in the country including stereotactic radiosurgery, robotic radiosurgery and the use of genomics for personalized treatment of cancer. Under the “Milann” brand, HCG operates 6 fertility centres. **For further information, visit www.hcgel.com or contact: Company Secretary and Compliance Officer: Sunu Manuel, investors@hcgoncology.com**

Disclaimer: daVinci, Tomotherapy and True Beam are registered trademarks of respective third parties and not of the Company.